Trademark Overview
On Tuesday, March 19, 2024, a trademark application was filed for XINVABRI with the United States Patent and Trademark Office. The USPTO has given the XINVABRI trademark a serial number of 98457633. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Monday, September 23, 2024. This trademark is owned by Pfizer Inc.. The XINVABRI trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; Pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; Pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations, and smoking cessation preparations; Vaccines for human use